$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Announces $16.1 Million Private Placement

$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
3 MINUTES AGO, 8:05 AM EST
VIA GLOBENEWSWIRE
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity syndrome (ICANS)

$Marker Therapeutics (MRKR.US)$
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Tuesday, 17th December at 7:00 am
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and...

$Marker Therapeutics (MRKR.US)$ its been long enough for company to gather data and present. what do you say?

$Marker Therapeutics (MRKR.US)$ my little MRKR woke up! wondering do you have news coming 😊

$Marker Therapeutics (MRKR.US)$ Reuters· just
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma

$Marker Therapeutics (MRKR.US)$
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...

$Marker Therapeutics (MRKR.US)$ All small biotech companies sell shares on good news, why did Marker previously cancel their sale? Does anyone have any ideas or reason?

$Marker Therapeutics (MRKR.US)$ I say within 6 to 8 weeks data will be released. please take note